[1] |
FANG Meilin, ZHENG Huimin, WANG Cunze, WANG Ling, RUAN Junshan.
One case of generalized myalgia caused by oxaliplatin
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 208-210.
|
[2] |
YANG Minghan, QIAO Meiling, LUO Jiaoyang, YANG Meihua, SHENG Ping.
Acute toxicity of anti-gastric cancer active ingredients of Ferula ferulaeoides
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(8): 880-884.
|
[3] |
ZHANG Xialan, YUAN Jing, WU Bin, QIN Yuanyuan.
Medications of apatinib mesylate in patients with malignant tumors
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(8): 927-932.
|
[4] |
WANG Ran, LI Yifan, LIU Xiaoyan, FENG Xin.
One case of pharmaceutical care of drug exposure during pregnancy
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(8): 933-934.
|
[5] |
LIU Jing, XIA Liang, ZHANG Shijie.
Pharmaceutical care of a patient with acute pancreatitis complicated with multiple drug allergy undergoing drug stimulation test
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(7): 822-824.
|
[6] |
WANG Ran, FENG Xin, DU Boran.
Advances in risk assessment and pharmaceutical care of pregnancy medication exposure during perinatal period
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(7): 836-840.
|
[7] |
LI Rongrong, LI Meng, GOU Yue, LUO Qiong, LYU Hua, SUN Xin, LIU Chenghai.
Clinical characteristics and risk factors of 113 cases of anti-neoplastic drug-induced liver injury
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(5): 505-510.
|
[8] |
HUO Peiqiong, ZHENG Peng, SU Zhenhao.
Pharmacovigilance in retail pharmacies for special or major diseases
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(4): 428-432.
|
[9] |
JIAO Fuzhi, CHEN Yarui, JI Wei, HAO Jianpeng, GUAN Quanlin.
Short-term efficacy and safety evaluation of PD-1 inhibitor combined with chemotherapy as a first-line neoadjuvant therapy for locally advanced gastric adenocarcinoma
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(3): 301-305.
|
[10] |
YANG Yan, ZHOU Dexi, WU Xinli, XUE Shuya, DING Haihua, ZHANG Quan, ZHANG Yunling.
Eighty-four cases of adverse drug reactions caused by novel anti-tumor drugs
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(3): 334-338.
|
[11] |
DING Qian, LI Boyu, ZHANG Qingxia.
Analysis of one case of hemorrhagic goiter caused by aspirin tablets in one patient with coronary heart disease
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(2): 209-212.
|
[12] |
YAO Xin, GE Qiuge, LI Yamin, WANG Yifan, LI Yuanyuan, LIU Zhiqiang.
Adverse drug reactions caused by new anti-tumor drugs from 2018 to 2022 in one hospital
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(11): 1273-1278.
|
[13] |
ZHENG Jinfeng, WANG Jinghong.
Pharmaceutical care of one case of malignant arrhythmia induced by multidrug combination
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(11): 1279-1281.
|
[14] |
SU Su, WU Shiqi, ZHANG Qingxia, YAN Suying.
Pharmaceutical care of a patient with indapamide-induced agranulocytosis
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(11): 1282-1285.
|
[15] |
WANG Rumeng, GUO Ziqi, YANG Hongxin, YANG Yong.
Mechanisms of Piper longum for treating gastric cancer based on network pharmacology and molecular docking
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(10): 1121-1128.
|